Early evidence indicated that pharmacological inhibition of HIF1 and HIF2α attenuated hypoxia-induced pulmonary hypertension, RV hypertrophy and PA remodeling by inhibiting intracellular Ca2+ release and pH changes upon hypoxia in PASMC (207). Here, EPAS1 is linked to pulmonary arterial hypertension.